Overview

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is determine whether or not tamoxifen reduces the chance of Hodgkin's Disease survivors developing breast cancer.
Phase:
N/A
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
AstraZeneca
Brigham and Women's Hospital
Massachusetts General Hospital
Treatments:
Tamoxifen